Jupiter Neurosciences, Inc. announced the publication in the Journal of Alzheimer's Disease of "JOTROL™, a Novel Formulation of Resveratrol, Shows Beneficial Effects in the 3xTg-AD Mouse Model." This research, performed in collaboration with the University of Miami Miller School of Medicine demonstrated that a novel, oral formulation of resveratrol, JOTROL™, was able to deliver therapeutically viable levels of resveratrol in a disease mouse model of Alzheimer's disease (AD). The results showed that JOTROL™ significantly increased bioavailability over non-formulated resveratrol and that treatment resulted in AD-related gene expression changes, as well as changes in inflammatory gene and cytokine levels. JOTROL™ may be effective as a prophylaxis and/or treatment for AD through increased expression and/or activation of neuroprotective genes, suppression of pro-inflammatory genes, and regulation of central and peripheral cytokine levels.